Insulin Glargine Safety in Pregnancy
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 26 of the 26 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Insulin glargine (Lantus) is an extended-action insulin analog with greater stability and duration of action than regular human insulin. The long duration of action and decreased incidence of hypoglycemia provide potential advantages for its use in pregnancy. However, the placental pharmacokinetics of insulin glargine have not been studied. Therefore, the objective of this study was to determine whether insulin glargine crosses the human placenta using the human perfused placental lobule technique. RESEARCH DESIGN AND METHODS: Placentae were obtained with informed consent after elective cesarean section delivery of noncomplicated term pregnancies. Insulin glargine, at a therapeutic concentration of 150 pmol/l (20 μU/ml) was added to the maternal circulation. Additional experiments were carried out at insulin glargine concentrations 1,000-fold higher than therapeutic levels (150, 225, and 300 nmol/l). A subsequent perfusion for which the maternal circuit remained open and insulin glargine was continuously infused at 150 pmol/l was completed for further confirmation of findings. The appearance of insulin glargine in the fetal circulation was analyzed by a chemiluminescence immunoassay. RESULTS: Results from perfusions carried out at therapeutic concentrations (150 pmol/l) of insulin glargine showed no detectable insulin glargine in the fetal circuit. After perfusion with very high insulin glargine concentrations of 150, 225, and 300 nmol/l, the rate of transfer remained low at 0.079 ± 0.01, 0.14, and 0.064 pmol · min−1 · g tissue−1, respectively. CONCLUSIONS: Insulin glargine, when used at therapeutic concentrations, is not likely to cross the placenta.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Both of these long-acting insulin analogs, however, are widely used in pregnancy, with evidence of safety in this setting (33–37).”
From Diabetes and Pregnancy: An Endocrine Society Clinical Practice Guideline (2013) · cites this paper as [36]
In the citing paper
“Nonetheless, glargine is unlikely to cross the placenta (36),”
From Diabetes and Pregnancy: An Endocrine Society Clinical Practice Guideline (2013) · cites this paper as [36]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Insulin Degradation: Progress and Potential*
Duckworth, W. C., Bennett, R. G., & Hamel, F. G. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.5.0349 · Cited by 871 · cited 2×
“However, at very high concentrations, it has been suggested that non– receptor-mediated processes, such as pinocytosis, may also be involved in insulin transport across cell membranes in other tissues (14).”
BackgroundLepore, M., Pampanelli, S., Fanelli, C., Porcellati, F., Bartocci, L., Di Vincenzo, A., Cordoni, C., Costa, E., Brunetti, P., & Bolli, G. B. (2000) · Diabetes · doi:10.2337/diabetes.49.12.2142 · Cited by 818 · cited 1×
“Experimental period In a closed-circuit experiment, insulin glargine was added at a therapeutic concentration of 150 pmol/l (20 U/ml) to the maternal circulations (n 4) (22).”
MethodKurtzhals, P., Schäffer, L., Sørensen, A., Kristensen, C., Jonassen, I., Schmid, C., & Trüb, T. (2000) · Diabetes · doi:10.2337/diabetes.49.6.999 · Cited by 739 · cited 2×
“Although the evidence to date is conflicting (16), one study demonstrated that glargine has a six- to eightfold increased affinity for the IGF-1 receptor in the osteosarcoma cell line Saos/B10 (15).”
BackgroundYki-Järvinen, H., Dressler, A., Ziemen, M., & HOE 901/300s Study Group (2000) · Diabetes Care · doi:10.2337/diacare.23.8.1130 · Cited by 579
Managing preexisting diabetes for pregnancy
Kitzmiller, J. L., Block, J. M., Brown, F. M., Catalano, P. M., Conway, D. L., Coustan, D. R., Gunderson, E. P., Herman, W. H., Hoffman, L. D., Inturrisi, M., et al. (2008) · Diabetes Care · doi:10.2337/dc08-9020 · Cited by 476
Maternal postprandial glucose levels and infant birth weight: the diabetes in early pregnancy study
Jovanovic-Peterson, L., Peterson, C. M., Reed, G. F., Metzger, B. E., Mills, J. L., Knopp, R. H., & Aarons, J. H. (1991) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(91)90637-7 · Cited by 411 · cited 1×
“Such insulins may be particularly useful in pregnancy because tight glycemic control during gestation decreases the risk of maternal and fetal complications (5–10) and attenuates their severity (9).”
BackgroundPreconception Care of Diabetes: Glycemic Control Prevents Congenital Anomalies
Kitzmiller, J. L. (1991) · JAMA · doi:10.1001/jama.1991.03460060063025 · Cited by 397
Reduced Hypoglycemia Risk With Insulin Glargine
Rosenstock, J., Dailey, G., Massi-Benedetti, M., Fritsche, A., Lin, Z., & Salzman, A. (2005) · Diabetes Care · doi:10.2337/diacare.28.4.950 · Cited by 371
Maternal postprandial glucose levels and infant birth weight: The Diabetes in Early Pregnancy Study
Jovanovic‐Peterson, L., Peterson, C., Reed, G., Metzger, B., Mills, J., Knopp, R., & Aarons, J. (1991) · International Journal of Gynecology & Obstetrics · doi:10.1016/0020-7292(91)90499-u · Cited by 322
Plank, J., Bodenlenz, M., Sinner, F., Magnes, C., Görzer, E., Regittnig, W., Endahl, L. A., Draeger, E., Zdravkovic, M., & Pieber, T. R. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1107 · Cited by 271 · cited 1×
“These long-acting insulins have the advantage of a very long elimination half-life (24 h), avoiding a peak in insulin concentrations (1,2).”
Background
Research works printed but not linked: 1
- Ciaraldi, 2005, Effects of the rapid-acting insulin analogue insulin glargine on cultured human skeletal muscle cells: comparisons to insulin and insulin-like growth factor-1, J Clin Endocrinol Metab, 86, 5838, 10.1210/jcem.86.12.8110 · doi:10.1210/jcem.86.12.8110 · Paper page
Cited by
Items 101–104 of 104
Consoli, A. (2018) · Endocrinology · doi:10.1007/978-3-319-27317-4_21-1
Inpatient Management of Diabetes During Pregnancy
Nassar, R., Lam, D. W.-H., & Shah, N. A. (2023) · Contemporary Endocrinology · doi:10.1007/978-3-031-44648-1_17
Her, T. K., Chung, G., Regal, R., Gregg, B. E., Bernal‐Mizrachi, E., WERNIMONT, S., & Alejandro, E. U. (2026) · Journal of Developmental Origins of Health and Disease · doi:10.1017/s2040174426100671
Toledano, Y., & Hod, M. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-13265-0.00008-2
Metadata
- Authors
- Pollex, E. K., Feig, D. S., Lubetsky, A., Yip, P. M., & Koren, G.
- Affiliations
- University of Toronto (CA)
- Mount Sinai Hospital (CA)
- Hospital for Sick Children (CA)
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
- Corresponding author
- Koren, Gideon
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2009-10-06
- Volume
- 33
- Issue
- 1
- Pages
- 29-33
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC2797979
- OpenAlex
- W2083261524
- Cited by
- 104
- References
- 26
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 4 · 2023: 3 · 2022: 5 · 2021: 4 · 2020: 7 · 2019: 4 · 2018: 10 · 2017: 3 · 2016: 4 · 2015: 7 · 2014: 5 · 2013: 10 · 2012: 7
- FWCI
- 11.04
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Hospital for Sick Children
- Canadian Institutes of Health Research
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
- Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Diabetes Research and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- insulin glargine, placental transfer, pregnancy, insulin analogues, placental perfusion, diabetes in pregnancy, drug safety in pregnancy
- MeSH terms
- Insulin Glargine, Biological Transport, Female, Fetal Blood, Humans, Hypoglycemic Agents, Insulin, Maternal-Fetal Exchange, Perfusion, Placenta, Pregnancy, Insulin, Long-Acting, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.